Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Adv Drug Deliv Rev. 2020 Jun 29;156:188–213. doi: 10.1016/j.addr.2020.06.020

Fig. 16.

Fig. 16.

Magnetofection of tumors with pDNAGFP or pDNAIL-12 using SPIONs-PAA-PEI: (a) Micrographs of frozen murine melanoma B16F1 and mammary adenocarcinoma TS/A tumor sections under phase contrast (PC) and epi-fluorescence illumination (FL) after transfection with pDNAGFP using (A) magnetofection, (B) SPIONs-PAA-PEI in the absence of magnetic field, (C) electrotransfer. Scale bar, 50 mm. (b) Antitumor effect of intratumoral administration of pDNAIL-12 on TS/A mammary adenocarcinoma tumors after magnetofection with SPIONs-PAA-PEI and electrotransfer. Blue arrows represent three consecutive treatments with pDNAIL-12. Tumor growth delay was calculated on the 10th day. (Adapted from ref. 304).